Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：332頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Diffuse Large B-Cell Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2014’, provides an overview of the Diffuse Large B-Cell Lymphoma’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diffuse Large B-Cell Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview 10
Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis 11
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 12
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Diffuse Large B-Cell Lymphoma - Products under Development by Companies 22
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 25
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 26
Bristol-Myers Squibb Company 26
F. Hoffmann-La Roche Ltd. 27
Amgen Inc. 28
Sanofi 29
AstraZeneca PLC 30
GlaxoSmithKline plc 31
Seattle Genetics, Inc. 32
Genentech, Inc. 33
MedImmune, LLC 34
Gilead Sciences, Inc. 35
Merck & Co., Inc. 36
Infinity Pharmaceuticals, Inc. 37
Celltrion, Inc. 38
Millennium Pharmaceuticals, Inc. 39
Novartis AG 40
Astellas Pharma Inc. 41
ImmunoGen, Inc. 42
Genmab A/S 43
Celgene Corporation 44
Incyte Corporation 45
Immunomedics, Inc. 46
Idera Pharmaceuticals, Inc. 47
Portola Pharmaceuticals, Inc. 48
Pharmacyclics, Inc. 49
Senesco Technologies, Inc. 50
Spectrum Pharmaceuticals, Inc. 51
Memgen, LLC. 52
Respiratorius AB 53
ProNAi Therapeutics, Inc. 54
CureTech Ltd. 55
Cell>Point 56
Aprogen, Inc. 57
Selvita S.A 58
Kite Pharma, Inc. 59
Arrien Pharmaceuticals, LLC 60
AbbVie Inc. 61
Amgen Astellas BioPharma K.K. 62
Pharmapraxis 63
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Target 65
Assessment by Mechanism of Action 69
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 78
obinutuzumab - Drug Profile 78
ibrutinib - Drug Profile 81
everolimus - Drug Profile 85
ibritumomab tiuxetan - Drug Profile 89
lenalidomide - Drug Profile 90
ofatumumab - Drug Profile 93
rituximab biosimilar - Drug Profile 97
bendamustine - Drug Profile 98
alisertib - Drug Profile 100
SAR-3419 - Drug Profile 103
blinatumomab - Drug Profile 105
brentuximab vedotin - Drug Profile 108
mocetinostat - Drug Profile 113
panobinostat - Drug Profile 116
bortezomib - Drug Profile 122
ruxolitinib phosphate - Drug Profile 127
idelalisib - Drug Profile 131
ISF-35 - Drug Profile 133
pidilizumab - Drug Profile 135
MEDI-551 - Drug Profile 137
epratuzumab - Drug Profile 139
CTL-019 - Drug Profile 144
vorinostat - Drug Profile 146
buparlisib hydrochloride - Drug Profile 149
PNT-2258 - Drug Profile 152
RG-7593 - Drug Profile 154
RG-7596 - Drug Profile 156
GS-9973 - Drug Profile 158
sotrastaurin acetate - Drug Profile 159
SNS-01T - Drug Profile 161
ISIS-STAT3Rx - Drug Profile 163
valproate sodium - Drug Profile 164
Allogeneic CD19CAR-TCM cells - Drug Profile 165
Engineered Peripheral Blood Autologous T Cell Therapeutics (eACT) Program - Drug Profile 166
pevonedistat hydrochloride - Drug Profile 167
ulocuplumab - Drug Profile 169
CC-223 - Drug Profile 170
CC-292 - Drug Profile 171
duvelisib - Drug Profile 173
rituximab biosimilar - Drug Profile 175
Dendritic Cell Vaccine - Drug Profile 177
AMG-319 - Drug Profile 178
IMGN-529 - Drug Profile 179
venetoclax - Drug Profile 180
CC-122 - Drug Profile 183
Anti-CD19-CAR-Transduced T Cells - Drug Profile 185
BCL-6 Inhibitor - Drug Profile 186
rituximab biosimilar - Drug Profile 187
rituximab biosimilar - Drug Profile 189
Platinum-Ethylenedicysteine-Glucosamine - Drug Profile 190
187 Rhenium-Ethylenedicysteine - N- AcetylGlucosamine - Drug Profile 191
IMO-8400 - Drug Profile 193
ND-2110 - Drug Profile 195
ND-2158 - Drug Profile 197
BLyS-Gelonin Fusion Toxin - Drug Profile 199
PRT-060318 - Drug Profile 200
pecazine - Drug Profile 201
thioridazine - Drug Profile 202
SEL24-B489 - Drug Profile 203
Compound 79-6 - Drug Profile 204
rituximab biosimilar - Drug Profile 205
ARN-3236 - Drug Profile 206
NBD peptide - Drug Profile 207
BTK Inhibitor Program - Drug Profile 208
Multiple Lead Series Targeting IRAK4 - Drug Profile 209
Andrographolide - Drug Profile 211
MALT-1 Inhibitors - Drug Profile 212
rituximab biosimilar - Drug Profile 213
Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates 214
Diffuse Large B-Cell Lymphoma - Dormant Projects 314
Diffuse Large B-Cell Lymphoma - Discontinued Products 315
Diffuse Large B-Cell Lymphoma - Product Development Milestones 316
Featured News & Press Releases 316
Appendix 326
Methodology 326
Coverage 326
Secondary Research 326
Primary Research 326
Expert Panel Validation 326
Contact Us 327
Disclaimer 327
List of Tables
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2014 15
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 18
Number of Products under Development by Companies, H1 2014 (Contd..1) 19
Number of Products under Development by Companies, H1 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2014 22
Comparative Analysis by Late Stage Development, H1 2014 23
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Development, H1 2014 25
Comparative Analysis by Unknown Stage Development, H1 2014 26
Products under Development by Companies, H1 2014 27
Products under Development by Companies, H1 2014 (Contd..1) 28
Products under Development by Companies, H1 2014 (Contd..2) 29
Products under Investigation by Universities/Institutes, H1 2014 30
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 31
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 32
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H1 2014 33
Diffuse Large B-Cell Lymphoma - Pipeline by Sanofi, H1 2014 34
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca PLC, H1 2014 35
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline plc, H1 2014 36
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014 37
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H1 2014 38
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2014 39
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 40
Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 41
Diffuse Large B-Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 42
Diffuse Large B-Cell Lymphoma - Pipeline by Celltrion, Inc., H1 2014 43
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 44
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H1 2014 45
Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2014 46
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2014 47
Diffuse Large B-Cell Lymphoma - Pipeline by Genmab A/S, H1 2014 48
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H1 2014 49
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H1 2014 50
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H1 2014 51
Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 52
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 53
Diffuse Large B-Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 54
Diffuse Large B-Cell Lymphoma - Pipeline by Senesco Technologies, Inc., H1 2014 55
Diffuse Large B-Cell Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 56
Diffuse Large B-Cell Lymphoma - Pipeline by Memgen, LLC., H1 2014 57
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB., H1 2014 58
Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2014 59
Diffuse Large B-Cell Lymphoma - Pipeline by CureTech Ltd., H1 2014 60
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, H1 2014 61
Diffuse Large B-Cell Lymphoma - Pipeline by Aprogen, Inc., H1 2014 62
Diffuse Large B-Cell Lymphoma - Pipeline by Selvita S.A, H1 2014 63
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2014 64
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 65
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H1 2014 66
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 67
Diffuse Large B-Cell Lymphoma - Pipeline by Pharmapraxis, H1 2014 68
Assessment by Monotherapy Products, H1 2014 69
Number of Products by Stage and Target, H1 2014 72
Number of Products by Stage and Mechanism of Action, H1 2014 76
Number of Products by Stage and Route of Administration, H1 2014 79
Number of Products by Stage and Molecule Type, H1 2014 82
Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 219
Diffuse Large B-Cell Lymphoma - Dormant Projects, H1 2014 319
Diffuse Large B-Cell Lymphoma - Discontinued Products, H1 2014 320
List of Figures
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2014 15
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 17
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Products, H1 2014 25
Assessment by Monotherapy Products, H1 2014 69
Number of Products by Top 10 Target, H1 2014 70
Number of Products by Stage and Top 10 Target, H1 2014 71
Number of Products by Top 10 Mechanism of Action, H1 2014 74
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 75
Number of Products by Top 10 Route of Administration, H1 2014 78
Number of Products by Stage and Top 10 Route of Administration, H1 2014 79
Number of Products by Top 10 Molecule Type, H1 2014 80
Number of Products by Stage and Top 10 Molecule Type, H1 2014 81
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diffuse Large B-Cell Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview 10
Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis 11
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 12
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 16
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Diffuse Large B-Cell Lymphoma - Products under Development by Companies 22
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 25
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 26
Bristol-Myers Squibb Company 26
F. Hoffmann-La Roche Ltd. 27
Amgen Inc. 28
Sanofi 29
AstraZeneca PLC 30
GlaxoSmithKline plc 31
Seattle Genetics, Inc. 32
Genentech, Inc. 33
MedImmune, LLC 34
Gilead Sciences, Inc. 35
Merck & Co., Inc. 36
Infinity Pharmaceuticals, Inc. 37
Celltrion, Inc. 38
Millennium Pharmaceuticals, Inc. 39
Novartis AG 40
Astellas Pharma Inc. 41
ImmunoGen, Inc. 42
Genmab A/S 43
Celgene Corporation 44
Incyte Corporation 45
Immunomedics, Inc. 46
Idera Pharmaceuticals, Inc. 47
Portola Pharmaceuticals, Inc. 48
Pharmacyclics, Inc. 49
Senesco Technologies, Inc. 50
Spectrum Pharmaceuticals, Inc. 51
Memgen, LLC. 52
Respiratorius AB 53
ProNAi Therapeutics, Inc. 54
CureTech Ltd. 55
Cell>Point 56
Aprogen, Inc. 57
Selvita S.A 58
Kite Pharma, Inc. 59
Arrien Pharmaceuticals, LLC 60
AbbVie Inc. 61
Amgen Astellas BioPharma K.K. 62
Pharmapraxis 63
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 64
Assessment by Monotherapy Products 64
Assessment by Target 65
Assessment by Mechanism of Action 69
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 78
obinutuzumab - Drug Profile 78
ibrutinib - Drug Profile 81
everolimus - Drug Profile 85
ibritumomab tiuxetan - Drug Profile 89
lenalidomide - Drug Profile 90
ofatumumab - Drug Profile 93
rituximab biosimilar - Drug Profile 97
bendamustine - Drug Profile 98
alisertib - Drug Profile 100
SAR-3419 - Drug Profile 103
blinatumomab - Drug Profile 105
brentuximab vedotin - Drug Profile 108
mocetinostat - Drug Profile 113
panobinostat - Drug Profile 116
bortezomib - Drug Profile 122
ruxolitinib phosphate - Drug Profile 127
idelalisib - Drug Profile 131
ISF-35 - Drug Profile 133
pidilizumab - Drug Profile 135
MEDI-551 - Drug Profile 137
epratuzumab - Drug Profile 139
CTL-019 - Drug Profile 144
vorinostat - Drug Profile 146
buparlisib hydrochloride - Drug Profile 149
PNT-2258 - Drug Profile 152
RG-7593 - Drug Profile 154
RG-7596 - Drug Profile 156
GS-9973 - Drug Profile 158
sotrastaurin acetate - Drug Profile 159
SNS-01T - Drug Profile 161
ISIS-STAT3Rx - Drug Profile 163
valproate sodium - Drug Profile 164
Allogeneic CD19CAR-TCM cells - Drug Profile 165
Engineered Peripheral Blood Autologous T Cell Therapeutics (eACT) Program - Drug Profile 166
pevonedistat hydrochloride - Drug Profile 167
ulocuplumab - Drug Profile 169
CC-223 - Drug Profile 170
CC-292 - Drug Profile 171
duvelisib - Drug Profile 173
rituximab biosimilar - Drug Profile 175
Dendritic Cell Vaccine - Drug Profile 177
AMG-319 - Drug Profile 178
IMGN-529 - Drug Profile 179
venetoclax - Drug Profile 180
CC-122 - Drug Profile 183
Anti-CD19-CAR-Transduced T Cells - Drug Profile 185
BCL-6 Inhibitor - Drug Profile 186
rituximab biosimilar - Drug Profile 187
rituximab biosimilar - Drug Profile 189
Platinum-Ethylenedicysteine-Glucosamine - Drug Profile 190
187 Rhenium-Ethylenedicysteine - N- AcetylGlucosamine - Drug Profile 191
IMO-8400 - Drug Profile 193
ND-2110 - Drug Profile 195
ND-2158 - Drug Profile 197
BLyS-Gelonin Fusion Toxin - Drug Profile 199
PRT-060318 - Drug Profile 200
pecazine - Drug Profile 201
thioridazine - Drug Profile 202
SEL24-B489 - Drug Profile 203
Compound 79-6 - Drug Profile 204
rituximab biosimilar - Drug Profile 205
ARN-3236 - Drug Profile 206
NBD peptide - Drug Profile 207
BTK Inhibitor Program - Drug Profile 208
Multiple Lead Series Targeting IRAK4 - Drug Profile 209
Andrographolide - Drug Profile 211
MALT-1 Inhibitors - Drug Profile 212
rituximab biosimilar - Drug Profile 213
Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates 214
Diffuse Large B-Cell Lymphoma - Dormant Projects 314
Diffuse Large B-Cell Lymphoma - Discontinued Products 315
Diffuse Large B-Cell Lymphoma - Product Development Milestones 316
Featured News & Press Releases 316
Appendix 326
Methodology 326
Coverage 326
Secondary Research 326
Primary Research 326
Expert Panel Validation 326
Contact Us 327
Disclaimer 327
List of Tables
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2014 15
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 18
Number of Products under Development by Companies, H1 2014 (Contd..1) 19
Number of Products under Development by Companies, H1 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2014 22
Comparative Analysis by Late Stage Development, H1 2014 23
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Development, H1 2014 25
Comparative Analysis by Unknown Stage Development, H1 2014 26
Products under Development by Companies, H1 2014 27
Products under Development by Companies, H1 2014 (Contd..1) 28
Products under Development by Companies, H1 2014 (Contd..2) 29
Products under Investigation by Universities/Institutes, H1 2014 30
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2014 31
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 32
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H1 2014 33
Diffuse Large B-Cell Lymphoma - Pipeline by Sanofi, H1 2014 34
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca PLC, H1 2014 35
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline plc, H1 2014 36
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2014 37
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H1 2014 38
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2014 39
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2014 40
Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2014 41
Diffuse Large B-Cell Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 42
Diffuse Large B-Cell Lymphoma - Pipeline by Celltrion, Inc., H1 2014 43
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 44
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H1 2014 45
Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2014 46
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2014 47
Diffuse Large B-Cell Lymphoma - Pipeline by Genmab A/S, H1 2014 48
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H1 2014 49
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H1 2014 50
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H1 2014 51
Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 52
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 53
Diffuse Large B-Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2014 54
Diffuse Large B-Cell Lymphoma - Pipeline by Senesco Technologies, Inc., H1 2014 55
Diffuse Large B-Cell Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 56
Diffuse Large B-Cell Lymphoma - Pipeline by Memgen, LLC., H1 2014 57
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB., H1 2014 58
Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2014 59
Diffuse Large B-Cell Lymphoma - Pipeline by CureTech Ltd., H1 2014 60
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, H1 2014 61
Diffuse Large B-Cell Lymphoma - Pipeline by Aprogen, Inc., H1 2014 62
Diffuse Large B-Cell Lymphoma - Pipeline by Selvita S.A, H1 2014 63
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2014 64
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 65
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H1 2014 66
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 67
Diffuse Large B-Cell Lymphoma - Pipeline by Pharmapraxis, H1 2014 68
Assessment by Monotherapy Products, H1 2014 69
Number of Products by Stage and Target, H1 2014 72
Number of Products by Stage and Mechanism of Action, H1 2014 76
Number of Products by Stage and Route of Administration, H1 2014 79
Number of Products by Stage and Molecule Type, H1 2014 82
Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2014 219
Diffuse Large B-Cell Lymphoma - Dormant Projects, H1 2014 319
Diffuse Large B-Cell Lymphoma - Discontinued Products, H1 2014 320
List of Figures
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2014 15
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 17
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 24
Comparative Analysis by Early Stage Products, H1 2014 25
Assessment by Monotherapy Products, H1 2014 69
Number of Products by Top 10 Target, H1 2014 70
Number of Products by Stage and Top 10 Target, H1 2014 71
Number of Products by Top 10 Mechanism of Action, H1 2014 74
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 75
Number of Products by Top 10 Route of Administration, H1 2014 78
Number of Products by Stage and Top 10 Route of Administration, H1 2014 79
Number of Products by Top 10 Molecule Type, H1 2014 80
Number of Products by Stage and Top 10 Molecule Type, H1 2014 81
